Kanjinti (trastuzumab)

pCPA File Number: 21722

Negotiation Status:

Concluded with an LOI

Indication(s):

Metastatic breast cancer (HER2-positive) in patients who have not received prior antiHER2 therapy or chemotherapy for metastatic disease

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2022-02-16

Negotiation Process Concluded:

2022-05-16